Learning and Generalization in Schizophrenia: Effects of Disease and Antipsychotic Drug Treatment

Daphna Shohamy, Perry Mihalakos, Ronald Chin, Binu Thomas, Anthony D. Wagner, Carol Tamminga

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: Schizophrenia involves alterations in hippocampal function. The implications of these alterations for memory function in the illness remain poorly understood. Furthermore, it remains unknown how memory is impacted by drug treatments for schizophrenia. The goal of this study was to delineate specific memory processes that are disrupted in schizophrenia and explore how they are affected by medication. We specifically focus on memory generalization-the ability to flexibly generalize memories in novel situations. Methods: Individuals with schizophrenia (n = 56) and healthy control subjects (n = 20) were tested on a computerized memory generalization paradigm. Participants first engaged in trial-by-error associative learning. They were then asked to generalize what they learned by responding to novel stimulus combinations. Individuals with schizophrenia were tested on or off antipsychotic medication, using a between-subject design in order to eliminate concerns about learning-set effects. Results: Individuals with schizophrenia were selectively impaired in their ability to generalize knowledge, despite having intact learning and memory accuracy. This impairment was found only in individuals tested off medication. Individuals tested on medication generalized almost as well as healthy control subjects. This between-group difference was selective to memory generalization. Conclusions: These findings suggest that individuals with schizophrenia have a selective alteration in the ability to flexibly generalize past experience toward novel learning environments. This alteration is unaccompanied by global memory impairments. Additionally, the results indicate a robust generalization difference on the basis of medication status. These results suggest that hippocampal abnormalities in schizophrenia might be alleviated with antipsychotic medication, with important implications for understanding adaptive memory-guided behavior.

Original languageEnglish (US)
Pages (from-to)926-932
Number of pages7
JournalBiological Psychiatry
Volume67
Issue number10
DOIs
StatePublished - May 15 2010

Fingerprint

Antipsychotic Agents
Schizophrenia
Learning
Aptitude
Therapeutics
Healthy Volunteers
Generalization (Psychology)
Pharmaceutical Preparations

Keywords

  • Antipsychotic drugs
  • hippocampus
  • human
  • memory
  • schizophrenia

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

Learning and Generalization in Schizophrenia : Effects of Disease and Antipsychotic Drug Treatment. / Shohamy, Daphna; Mihalakos, Perry; Chin, Ronald; Thomas, Binu; Wagner, Anthony D.; Tamminga, Carol.

In: Biological Psychiatry, Vol. 67, No. 10, 15.05.2010, p. 926-932.

Research output: Contribution to journalArticle

Shohamy, Daphna ; Mihalakos, Perry ; Chin, Ronald ; Thomas, Binu ; Wagner, Anthony D. ; Tamminga, Carol. / Learning and Generalization in Schizophrenia : Effects of Disease and Antipsychotic Drug Treatment. In: Biological Psychiatry. 2010 ; Vol. 67, No. 10. pp. 926-932.
@article{d327e449b04640a9ab7ff8dd7c50f5fd,
title = "Learning and Generalization in Schizophrenia: Effects of Disease and Antipsychotic Drug Treatment",
abstract = "Background: Schizophrenia involves alterations in hippocampal function. The implications of these alterations for memory function in the illness remain poorly understood. Furthermore, it remains unknown how memory is impacted by drug treatments for schizophrenia. The goal of this study was to delineate specific memory processes that are disrupted in schizophrenia and explore how they are affected by medication. We specifically focus on memory generalization-the ability to flexibly generalize memories in novel situations. Methods: Individuals with schizophrenia (n = 56) and healthy control subjects (n = 20) were tested on a computerized memory generalization paradigm. Participants first engaged in trial-by-error associative learning. They were then asked to generalize what they learned by responding to novel stimulus combinations. Individuals with schizophrenia were tested on or off antipsychotic medication, using a between-subject design in order to eliminate concerns about learning-set effects. Results: Individuals with schizophrenia were selectively impaired in their ability to generalize knowledge, despite having intact learning and memory accuracy. This impairment was found only in individuals tested off medication. Individuals tested on medication generalized almost as well as healthy control subjects. This between-group difference was selective to memory generalization. Conclusions: These findings suggest that individuals with schizophrenia have a selective alteration in the ability to flexibly generalize past experience toward novel learning environments. This alteration is unaccompanied by global memory impairments. Additionally, the results indicate a robust generalization difference on the basis of medication status. These results suggest that hippocampal abnormalities in schizophrenia might be alleviated with antipsychotic medication, with important implications for understanding adaptive memory-guided behavior.",
keywords = "Antipsychotic drugs, hippocampus, human, memory, schizophrenia",
author = "Daphna Shohamy and Perry Mihalakos and Ronald Chin and Binu Thomas and Wagner, {Anthony D.} and Carol Tamminga",
year = "2010",
month = "5",
day = "15",
doi = "10.1016/j.biopsych.2009.10.025",
language = "English (US)",
volume = "67",
pages = "926--932",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "10",

}

TY - JOUR

T1 - Learning and Generalization in Schizophrenia

T2 - Effects of Disease and Antipsychotic Drug Treatment

AU - Shohamy, Daphna

AU - Mihalakos, Perry

AU - Chin, Ronald

AU - Thomas, Binu

AU - Wagner, Anthony D.

AU - Tamminga, Carol

PY - 2010/5/15

Y1 - 2010/5/15

N2 - Background: Schizophrenia involves alterations in hippocampal function. The implications of these alterations for memory function in the illness remain poorly understood. Furthermore, it remains unknown how memory is impacted by drug treatments for schizophrenia. The goal of this study was to delineate specific memory processes that are disrupted in schizophrenia and explore how they are affected by medication. We specifically focus on memory generalization-the ability to flexibly generalize memories in novel situations. Methods: Individuals with schizophrenia (n = 56) and healthy control subjects (n = 20) were tested on a computerized memory generalization paradigm. Participants first engaged in trial-by-error associative learning. They were then asked to generalize what they learned by responding to novel stimulus combinations. Individuals with schizophrenia were tested on or off antipsychotic medication, using a between-subject design in order to eliminate concerns about learning-set effects. Results: Individuals with schizophrenia were selectively impaired in their ability to generalize knowledge, despite having intact learning and memory accuracy. This impairment was found only in individuals tested off medication. Individuals tested on medication generalized almost as well as healthy control subjects. This between-group difference was selective to memory generalization. Conclusions: These findings suggest that individuals with schizophrenia have a selective alteration in the ability to flexibly generalize past experience toward novel learning environments. This alteration is unaccompanied by global memory impairments. Additionally, the results indicate a robust generalization difference on the basis of medication status. These results suggest that hippocampal abnormalities in schizophrenia might be alleviated with antipsychotic medication, with important implications for understanding adaptive memory-guided behavior.

AB - Background: Schizophrenia involves alterations in hippocampal function. The implications of these alterations for memory function in the illness remain poorly understood. Furthermore, it remains unknown how memory is impacted by drug treatments for schizophrenia. The goal of this study was to delineate specific memory processes that are disrupted in schizophrenia and explore how they are affected by medication. We specifically focus on memory generalization-the ability to flexibly generalize memories in novel situations. Methods: Individuals with schizophrenia (n = 56) and healthy control subjects (n = 20) were tested on a computerized memory generalization paradigm. Participants first engaged in trial-by-error associative learning. They were then asked to generalize what they learned by responding to novel stimulus combinations. Individuals with schizophrenia were tested on or off antipsychotic medication, using a between-subject design in order to eliminate concerns about learning-set effects. Results: Individuals with schizophrenia were selectively impaired in their ability to generalize knowledge, despite having intact learning and memory accuracy. This impairment was found only in individuals tested off medication. Individuals tested on medication generalized almost as well as healthy control subjects. This between-group difference was selective to memory generalization. Conclusions: These findings suggest that individuals with schizophrenia have a selective alteration in the ability to flexibly generalize past experience toward novel learning environments. This alteration is unaccompanied by global memory impairments. Additionally, the results indicate a robust generalization difference on the basis of medication status. These results suggest that hippocampal abnormalities in schizophrenia might be alleviated with antipsychotic medication, with important implications for understanding adaptive memory-guided behavior.

KW - Antipsychotic drugs

KW - hippocampus

KW - human

KW - memory

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=77951623347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951623347&partnerID=8YFLogxK

U2 - 10.1016/j.biopsych.2009.10.025

DO - 10.1016/j.biopsych.2009.10.025

M3 - Article

C2 - 20034612

AN - SCOPUS:77951623347

VL - 67

SP - 926

EP - 932

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 10

ER -